Novartis AG (FRA:NOT0) Total Equity: €33,672 Mil (As of Mar. 2026)


FRA:NOT0 Novartis AG FRA:NOT0
83 GF Score
Price €18.20
GF Value €15.09
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis AG Total Equity?

Novartis AG FRA:NOT0 83 Total Equity is €33,672 Mil as of Mar. 2026. GuruFocus rates FRA:NOT0 with a GF Score™ of 83/100 and a GF Value™ of €15.09 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Novartis AG's total equity for the quarter that ended in Mar. 2026 was €33,672 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Novartis AG Total Equity Historical Data

* Premium members only.

The historical data trend for Novartis AG's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Total Equity Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60,022.47 56,095.31 42,869.75 42,140.33 39,752.85

Novartis AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35,568.10 36,460.82 38,128.70 39,752.85 33,671.86
FRA:NOT0
83GF Score
Novartis AG FRA:NOT0
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Novartis AG's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=94750.446-54997.6
=39,753

Novartis AG's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=102530.18-68858.325
=33,672

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €33,672 Mil mean?
Novartis AG (FRA:NOT0) has a Total Equity of €33,672 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Novartis AG and its competitors.
Is Novartis AG's Total Equity too high?
Novartis AG's current Total Equity is €33,672 Mil. Overall, Novartis AG has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Total Equity compare to LLY and JNJ?
Novartis AG's Total Equity of €33,672 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Novartis AG and its competitors. Novartis AG's current Total Equity is €33,672 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (FRA:NOT0) is currently considered Modestly Overvalued. The stock's GF Value™ is €15.09, compared to a current price of €18.20 — trading 20.6% above its estimated fair value. The current Total Equity is €33,672 Mil. Novartis AG's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Novartis AG (FRA:NOT0), the current Total Equity is €33,672 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (FRA:NOT0) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of €18.20 is trading 20.6% above its estimated GF Value™ of €15.09. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for FRA:NOT0:

  • Total Equity: €33,672 Mil
  • GF Value™: €15.09 vs. price of €18.20 (20.6% above fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the FRA:NOT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
83GF Score

Get the complete analysis for FRA:NOT0

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.20
Price
€15.09
GF Value